Nantahala Capital Management’s Cogent Biosciences COGT Stock Holding History

Nantahala Capital Management’s Portfolio COGT Stock Details COGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-250,000	Closed	-$9.62M	–	161
2026 Q1	$9.62M	Hold	250,000	–	–	0.35%	72
2025 Q4	$8.88M	Sell	250,000 -1,256,989	-83%	-$35.3M	0.29%	82
2025 Q3	$21.6M	Sell	1,506,989 -148,700	-9%	-$1.76M	0.75%	29
2025 Q2	$11.9M	Buy	1,655,689 +812,200	+96%	+$4.5M	0.47%	46
2025 Q1	$5.05M	Sell	843,489 -9,366	-1%	-$73.4K	0.2%	68
2024 Q4	$6.65M	Buy	852,855 +61,919	+8%	+$617K	0.29%	64
2024 Q3	$8.54M	Hold	790,936	–	–	0.43%	47
2024 Q2	$6.67M	Hold	790,936	–	–	0.39%	53
2024 Q1	$5.32M	Buy	790,936 +150,000	+23%	+$927K	0.3%	58
2023 Q4	$3.77M	Buy	640,936 +65,936	+11%	+$505K	0.23%	73
2023 Q3	$5.61M	Buy	575,000 +510,868	+797%	+$6.06M	0.48%	49
2023 Q2	$759K	Buy	+64,132	New	+$736K	0.07%	98

Other funds holding COGT

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jupiter Topco New York $245B AUM

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Nantahala Capital Management's COGT Position: Q2 2026 in Review

Nantahala Capital Management sold out of Cogent Biosciences (COGT) in Q2 2026, closing a stake of 250,000 shares — an estimated $9.62M sold.

Nantahala Capital Management first reported a position in COGT in Q2 2023 and held it in 12 quarters. The position peaked at $21.6M in Q3 2025. 323 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

Nantahala Capital Management reported no remaining Cogent Biosciences position as of Q2 2026 after selling out during the quarter.
Nantahala Capital Management sold 250,000 Cogent Biosciences shares in Q2 2026, an estimated $9.62M.
Nantahala Capital Management first reported a position in Cogent Biosciences in Q2 2023 and held it in 12 quarters.
Nantahala Capital Management's Cogent Biosciences position peaked at $21.6M in Q3 2025.
323 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Nantahala Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.